
Kiniksa Pharmaceuticals International Investor Relations Material
Latest events

Q1 2025
Kiniksa Pharmaceuticals International
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Kiniksa Pharmaceuticals International plc
Access all reports
Kiniksa Pharmaceuticals International, plc is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines. The company's work targets debilitating diseases with significant unmet medical needs, particularly within cardiovascular and autoimmune disorders. Kiniksa's portfolio includes products and candidates based on strong biological rationale or validated mechanisms, offering potential differentiation in treatment approaches. The company is known for its flagship product, ARCALYST, which is used to treat certain inflammatory cardiovascular conditions. The company is headquarted in London, UK, and its shares are listed on the NASDAQ.
Key slides for Kiniksa Pharmaceuticals International plc


Q4 2024
Kiniksa Pharmaceuticals International plc


Corporate Presentation
Kiniksa Pharmaceuticals International plc
Latest articles
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
Ticker symbol
KNSA
Country
🇺🇸 United States